Vijay Kuchroo

Vijay Kumar Kuchroo is the founder of Celsius Therapeutics, Inc., founded in 2018.
Dr. Kuchroo is also the founder of CoStim Pharmaceuticals, Inc.,Tempero Pharmaceuticals, Inc.,Tizona Therapeutics, Inc.,Larkspur Biosciences, Inc. Dr. Kuchroo currently serves as Director at Massachusetts Institute of Technology and Evergrande Centre For Immunologic Diseases.
Dr. Kuchroo is Co-Director-Infection & Immunity at Brigham Research Institute.
Dr. Kuchroo is Founding Director at Mass General Hospital.
Dr. Kuchroo is Member-Scientific Advisory Board at Potenza Therapeutics, Inc. Dr. Kuchroo is a Member at The Broad Institute, Inc. Dr. Kuchroo is Professor at Harvard Medical School.
Dr. Kuchroo is Venture Partner at Catalio Capital Management LP.
Former positions include Independent Non-Executive Director at Biocon Ltd. from 2015 to 2023, Independent Non-Executive Director at Syngene International Ltd., Independent Director at Bicara Therapeutics, Inc., and Senior Scientist at The Brigham & Women's Hospital, Inc. Education includes a doctorate from The University of Queensland conferred in 1985 and an undergraduate degree from Haryana Agricultural University conferred in 1976.